News

Enteris BioPharma’s “Feasibility-to-Licensing” Partner, Cara Therapeutics, Doses First Patient in Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ Study to evaluate Oral KORSUVA (CR845/difelikefalin) for the Treatment […]

Enteris BioPharma Announces Completion of Recruitment in Expanded Phase 2a Clinical Trial of Ovarest® (oral leuprolide tablet) for Endometriosis Additional treatment arm to examine improved formulation […]

Enteris BioPharma to Present at the 25th Annual Future Leaders in the Biotech Industry Conference BOONTON, N.J., March 15, 2018 /PRNewswire/ – Enteris BioPharma, Inc., a […]

Enteris BioPharma Initiates Feasibility Program with Ferring Pharmaceuticals to Develop an Oral Formulation of a Peptide Agreement to Target New Oral Peptide Development Opportunity, Extending Successful […]

Enteris BioPharma’s “Feasibility-to-Licensing” Partner, Cara Therapeutics, Doses First Patient in Phase 1 Trial of Oral KORSUVA™ Study to evaluate Peptelligence®-Engineered Oral CR845 (CR845/difelikefalin) in Chronic Liver […]

Enteris BioPharma Announces Positive Results from Phase 2a Clinical Trial of Ovarest® (oral leuprolide tablet) for Endometriosis Ovarest® Demonstrates Significant Suppression of Estradiol, Demonstrating Proof-of-Concept of […]

Enteris BioPharma’s “Feasibility-to-Licensing” Partner, Cara Therapeutics, Doses First Patient in Phase 1 Study of Peptelligence®-Engineered Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients Trial to evaluate […]